CSS
INZY

Cubist Systematic Strategies’s Inozyme Pharma INZY Stock Holding History

Cubist Systematic Strategies’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-83,919
Closed -$232K – 3155
2024
Q4 		$232K Buy
+83,919
New +$319K ﹤0.01% 2514
2024
Q3 		– Sell
-18,891
Closed -$84.3K – 3229
2024
Q2 		$84.3K Buy
+18,891
New +$91.6K ﹤0.01% 2653
2023
Q2 		– Sell
-50,712
Closed -$291K – 3900
2023
Q1 		$291K Buy
+50,712
New +$134K ﹤0.01% 3020

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's INZY Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 83,919 shares — an estimated $232K sold.

Cubist Systematic Strategies first reported a position in INZY in Q1 2023 and held it in 3 quarters. The position peaked at $291K in Q1 2023. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 83,919 Inozyme Pharma shares in Q1 2025, an estimated $232K.
  • Cubist Systematic Strategies first reported a position in Inozyme Pharma in Q1 2023 and held it in 3 quarters.
  • Cubist Systematic Strategies's Inozyme Pharma position peaked at $291K in Q1 2023.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.